search

menu

  • Research Research
    • Where science meets inspired minds

    • Back
    • Research
    • Our Science
    • Research Groups
    • Facilities & Platforms
    • Clinical research
    • Find a researcher
    • Publications
    • Knowledge Transfer
  • Careers & study Careers & study
    • Become a leader in cancer research

    • Back
    • Careers & study
    • Vacancies
    • Faculty
    • Scientific staff
    • Scientific support staff
    • Postdoctoral fellows
    • PhD Students
    • Operational staff
    • Clinical fellows
    • Life in Amsterdam
    • Student internships
  • News & Events News & Events
    • Check out our stories and events

    • Back
    • News & Events
    • News
    • Media & Press
    • Calendar
  • About us About us
    • Maximum impact for cancer patients

    • Back
    • About us
    • Our vision
    • Organization
    • Collaborations
    • Responsible Research
    • Support us
    • Visit us
    • Contact us
  • Support us
Support us
  • Home
  • Publications
  • Research
  • Publications
  • Article

Definition, diagnosis and treatment of oligometastatic oesophagogastric cancer: A Delphi consensus study in Europe.

Tiuri E Kroese ,
Hanneke W M van Laarhoven ,
Sebastian F Schoppman ,
Pieter R A J Deseyne ,
Eric van Cutsem ,
Karin Haustermans ,
Philippe Nafteux ,
Melissa Thomas ,
Radka Obermannova ,
Hanna R Mortensen ,
Marianne Nordsmark ,
Per Pfeiffer ,
Anneli Elme ,
Antoine Adenis ,
Guillaume Piessen ,
Christiane J Bruns ,
Florian Lordick ,
Ines Gockel ,
Markus Moehler ,
Cihan Gani ,
Theodore Liakakos ,
John Reynolds ,
Alessio G Morganti ,
Riccardo Rosati ,
Carlo Castoro ,
Francesco Cellini ,
Domenico D'Ugo ,
Franco Roviello ,
Maria Bencivenga ,
Giovanni de Manzoni ,
Mark I van Berge Henegouwen ,
Maarten C C M Hulshof ,
Jolanda van Dieren ,
Marieke Vollebergh ,
Johanna W van Sandick ,
Paul Jeene ,
Christel T Muijs ,
Marije Slingerland ,
Francine E M Voncken ,
Henk Hartgrink ,
Geert-Jan Creemers ,
Maurice J C van der Sangen ,
Grard Nieuwenhuijzen ,
Maaike Berbee ,
Marcel Verheij ,
Bas Wijnhoven ,
Laurens V Beerepoot ,
Nadia H Mohammad ,
Stella Mook ,
Jelle P Ruurda ,
Piotr Kolodziejczyk ,
Wojciech P Polkowski ,
Lucjan Wyrwicz ,
Maria Alsina ,
Manuel Pera ,
Tania F Kanonnikoff ,
Andrés Cervantes ,
Magnus Nilsson ,
Stefan Monig ,
Anna D Wagner ,
Matthias Guckenberger ,
Ewen A Griffiths ,
Elizabeth Smyth ,
George B Hanna ,
Sheraz Markar ,
M Asif Chaudry ,
Maria A Hawkins ,
Edward Cheong ,
Richard van Hillegersberg ,
Peter S N van Rossum ,

Abstract

METHODS

In total, 65 specialists in the multidisciplinary treatment for oesophagogastric cancer from 49 expert centres across 16 European countries were requested to participate in this Delphi study. The consensus finding process consisted of a starting meeting, 2 online Delphi questionnaire rounds and an online consensus meeting. Input for Delphi questionnaires consisted of (1) a systematic review on definitions of oligometastatic oesophagogastric cancer and (2) a discussion of real-life clinical cases by multidisciplinary teams. Experts were asked to score each statement on a 5-point Likert scale. The agreement was scored to be either absent/poor (<50%), fair (50%-75%) or consensus (≥75%).

CONCLUSION

The OMEC project has resulted in a multidisciplinary European consensus statement for the definition, diagnosis and treatment of oligometastatic oesophagogastric adenocarcinoma and squamous cell cancer. This can be used to standardise inclusion criteria for future clinical trials.

RESULTS

A total of 48 experts participated in the starting meeting, both Delphi rounds, and the consensus meeting (overall response rate: 71%). OMD was considered in patients with metastatic oesophagogastric cancer limited to 1 organ with ≤3 metastases or 1 extra-regional lymph node station (consensus). In addition, OMD was considered in patients without progression at restaging after systemic therapy (consensus). For patients with synchronous or metachronous OMD with a disease-free interval ≤2 years, systemic therapy followed by restaging to consider local treatment was considered as treatment (consensus). For metachronous OMD with a disease-free interval >2 years, either upfront local treatment or systemic treatment followed by restaging was considered as treatment (fair agreement).

BACKGROUND

Local treatment improves the outcomes for oligometastatic disease (OMD, i.e. an intermediate state between locoregional and widespread disseminated disease). However, consensus about the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer is lacking. The aim of this study was to develop a multidisciplinary European consensus statement on the definition, diagnosis and treatment of oligometastatic oesophagogastric cancer.

More about this publication

European journal of cancer (Oxford, England : 1990)

Volume 185
Pages 28-39
Publication date 01-05-2023

Full text links

Publisher website (DOI) 10.1016/j.ejca.2023.02.015
Europe PubMed Central 36947929
Pubmed 36947929

Where science meets inspired minds

Contact

Plesmanlaan 121
1066CX Amsterdam

020 512 9111 communicatie@nki.nl

Quick links

  • Vacancies
  • News
  • Contact us
  • Media & Press

Follow us on

Disclaimer
Privacy statement
Cookies
Change cookie settings

This site uses cookies

This website uses cookies to ensure you get the best experience on our website.